Clinical trials: Maintenance Phase
- Condition Maintenance Phase
- Funder type Industry (pharma, biotech, devices)
- Accepts healthy volunteers yes
Insomnia, Hepatic Impairment
Pharmacokinetics and Safety Study of YZJ-1139 in Subjects With Mild, Moderate and Normal Hepatic Impairment
Primary Objectives: To evaluate the effect of the subjects with mild (Child Pugh A), moderate (Child Pugh B) and normal hepatic impairment on the pharmacokinetics of YZJ-1139 Secondary Objectives: To evaluate the safety of a…
- Trial name
- NCT06671509
- Testing
- YZJ-1139
- Where
- China
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Shanghai Haiyan Pharmaceutical Technology Co., Ltd.
Insomnia
Study of MK0928 in Healthy Adult Volunteers in a Model of Insomnia (0928-006)(COMPLETED)
A study to evaluate the safety and effectiveness of Study of MK0928 in Healthy Adult Volunteers in a Model of Insomnia for insomnia (a sleep disorder).
- Trial name
- NCT00102167
- Testing
- gaboxadol
- Volunteers
- 663 people, healthy volunteers welcome
- Sponsor
- H. Lundbeck A/S
Healthy, Sleep Quality
Study to Investigate Effects of a Herbal Drug Compared to Placebo on Sleep
To demonstrate the influence of a herbal preparation containing hypericum, passionflower, and valerian on sleep structure, improvement of attention, and well-being in comparison to placebo.
- Trial name
- sleep-EEG (NCT00997256)
- Testing
- Neurapas® balance (Herbal product (Hypericum, Passionflower, Valerian)), film-coated sugar-pill
- Where
- Germany
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Pascoe Pharmazeutische Praeparate GmbH
Crohn Disease, Ulcerative Colitis
A Study to Evaluate the Effect of Ustekinumab on Cytochrome P450 Enzyme Activities Following Induction and Maintenance Dosing in Participants With Active Crohn's Disease or Ulcerative Colitis
The purpose of this study is to evaluate the potential effects of an intravenous (IV) induction and subcutaneous (SC) maintenance administration of ustekinumab on the pharmacokinetic (PK) of a cocktail of representative probe…
- Trial name
- NCT03358706
- Testing
- Ustekinumab IV Infusion, Ustekinumab SC Injection, Midazolam 2 mg
- Where
- 16 sites in United States, Belgium and 2 more
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Janssen Research & Development, LLC
Cold Symptoms
Efficacy and Safety of Imuneks 10 mg Capsules in the Prophylaxis of Cold
The objective of this study is to evaluate the efficacy and safety of Imuneks 10 mg Capsules in the prophylaxis of cold and the maintenance of the good health state in 70 healthy subjects.
- Trial name
- NCT02807220
- Testing
- Imuneks 10mg
- Where
- Turkey (Türkiye)
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Imuneks Farma ilac San. Tic. A.S.
End-Stage Renal Disease
A Pharmacokinetics, Pharmacodynamics and Safety Study of Single Dose of Rivaroxaban in Participants With End-Stage Renal Disease (ESRD) on Maintenance Hemodialysis
The purpose of this study is to assess the pharmacokinetics (the study of the way a drug enters and leaves the blood and tissues over time) and pharmacodynamics (the way a drug may change body function) of a single 15-milligram…
- Trial name
- NCT02289703
- Testing
- Rivaroxaban 15 mg
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Janssen Research & Development, LLC
Exercise, Health Behavior
Physical Activity Smartphone App for African American Men (FitBros) Phase I
Low physical activity levels contribute to African American men experiencing health disparities across a number of chronic diseases.
- Conditions
- Exercise, Health Behavior, Technology
- Trial name
- FitBros (NCT05509712)
- Testing
- Focus Groups to Refine MobileMen App Content, Beta testing of MobileMen App Prototype
- Where
- 3 sites in United States
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- Klein Buendel, Inc.
Bladder Function
Pilot Trial in Sleep Laboratory Setting to Compare the Physiology of Night Time Bladder Function in Subjects With Overactive Bladder (OAB) Versus Subjects That Have Insomnia and Healthy Normal Subjects
This is an observational, physiology pilot study of subjects with overactive bladder, insomnia and normal subjects. No study drug will be given. All subjects will complete a one week sleep diary and a 3-day bladder diary.
- Trial name
- Nocturia Plt 1 (NCT01029015)
- Testing
- cystometry, polysomnography
- Where
- United States
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Astellas Pharma Inc
Healthy
Next-Day Residual Effects of Gabapentin, Diphenhydramine and Triazolam on Simulated Driving Performance in Normal Volunteers
This study will examine the next-day residual effects of a nighttime dose of gabapentin 250 mg, diphenhydramine citrate 76 mg and triazolam 0.5 mg compared to placebo and each other on simulated driving performance in normal…
- Trial name
- NCT01888497
- Testing
- Gabapentin, Diphenhydramine citrate, Triazolam
- Where
- 4 sites in United States
- Volunteers
- 59 people, healthy volunteers welcome
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Chronic Pain, Anxiety
Phase II Trial of Nu-V3 Non-Invasive Nerve Stimulation Device for Chronic Pain, Anxiety, Depression, Sleeplessness
This Nu-V3 clinical study is a randomized, phase II, open-label study evaluating the Nu-V3 cranial nerve stimulation treatment device in patients with chronic pain, anxiety, depression, and/or sleeplessness.
- Conditions
- Chronic Pain, Anxiety, Depression, Sleeplessness
- Trial name
- Nu-V3P2RCT (NCT05394545)
- Testing
- Nu-V3
- Where
- 2 sites in United States
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Nu-Life Solutions
Acne Vulgaris
Efficacy and Tolerability Evaluation of a Novel Dermo-cosmetic Product for Mild-to-moderate Acne
The goal of this non-interventional, observational study is to evaluate the real-world efficacy and tolerance of a novel dermocosmetic cream containing 15% Azelaic acid and a complex of active ingredients (α-AZ cream) in patients…
- Trial name
- NCT07759505
- Where
- Romania
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- ISISPHARMA
HIV
TMC278-TiDP6-C121: Drug-drug Interaction Trial to Investigate the Potential Interaction Between TMC278 25 mg Daily and Methadone, at Steady State.
The purpose of this Phase I, open-label, single-sequence drug-drug interaction trial in patients on stable methadone maintenance therapy is to investigate the potential interaction between TMC278 25 mg daily and methadone, at…
- Trial name
- NCT00744770
- Testing
- TMC278
- Volunteers
- 13 people, healthy volunteers welcome
- Sponsor
- Tibotec Pharmaceuticals, Ireland
Healthy Participants
A Study to Investigate the Potential Interaction Between Telaprevir and Methadone, at Steady-State
The purpose of this study is to evaluate the effect of steady-state (constant concentration of medication in the blood) telaprevir 750 mg every 8 hours on the steady-state pharmacokinetics (how the drug concentrations change over…
- Trial name
- NCT00933283
- Testing
- Telaprevir, Methadone
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Tibotec BVBA
Psoriasis
A Study of the Safety and Efficacy of Infliximab in Patients With Psoriasis
The purpose of this study is to determine if infliximab (anti-TNF) is effective in the treatment of plaque psoriasis.
- Trial name
- NCT00106834
- Testing
- Infliximab
- Volunteers
- 378 people, healthy volunteers welcome
- Sponsor
- Centocor, Inc.
Insomnia, Renal Impairment
Pharmacokinetics and Safety Study of YZJ-1139 in Subjects With Severe Renal Impairment and Normal Renal Impairment
Objective： 1. To evaluate the pharmacokinetics of YZJ-1139 tablets in patients with severe renal impairment and in subjects with normal renal impairment. 2.
- Trial name
- NCT06671444
- Testing
- YZJ-1139
- Where
- 3 sites in China
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Shanghai Haiyan Pharmaceutical Technology Co., Ltd.
Sleep Initiation and Maintenance Disorders
A Study of LY2624803 in Japanese Participants With Transient Insomnia
The aim of this study is to learn how different doses of LY2624803 affect sleep in healthy Japanese participants. The study has four treatment periods.
- Trial name
- NCT01784614
- Testing
- LY2624803 - Solution, LY2624803 - Capsule
- Where
- Japan
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Hepatitis B, Poliomyelitis
Post-marketing Safety Study of GSK Biological's Pediarix™ Vaccine
Pre-licensure studies of GSK Biologicals' PEDIARIX vaccine have shown it to be generally safe and unlikely to result in vaccine-associated serious adverse events.
- Conditions
- Hepatitis B, Poliomyelitis, Diphtheria, Tetanus
- Trial name
- NCT00146835
- Testing
- Pediarix, Licensed DTPa containing vaccine, Prevnar®: (Wyeth)
- Volunteers
- 120,794 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Contraception
Investigating Ovulation Inhibition for Use as a Contraceptive
A single-centre, open-label, randomised, phase II study on the maintenance of ovulation inhibition after intentional application errors during 84 days of treatment with MR 130A 01 contraceptive transdermal patch
- Trial name
- NCT07365904
- Testing
- MR-130A-01 contraceptive transdermal patch, containing norelgestromin (NGMN)
- Where
- Germany
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Mylan Pharmaceuticals Inc
Transient Insomnia
A Study of LY2624803 in Participants With Transient Insomnia
The aim of this study is to learn how different doses of LY2624803 affect sleep in healthy people. The study has four treatment periods.
- Trial name
- NCT01779830
- Testing
- LY2624803 - Capsules, Zolpidem - Tablets
- Where
- France
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Psoriasis
Study to Evaluate Broadlumab vs Placebo and Ustekinumab
The purpose of the study is to evaluate the efficacy and safety of Induction and Maintenance Regimens of Brodalumab compared with Placebo and Ustekinumab in subjects with moderate to severe plaque psoriasis.
- Trial name
- AMAGINE-3 (NCT02786732)
- Testing
- 210mg Brodalumab, 140mg Brodalumab, Ustekinumab
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- MedDerm Associates